All In Biotech

Drug Trial Radar · NCT05251090

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for Injection

A Phase I, Multicentre, Open-label Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection in Children With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Jun 16, 2021

Primary completion

Nov 15, 2021

Study completion May 9, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection (FRSW107) Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in Severe Hemophilia A.

Conditions

  • Hemophilia A

Interventions

  • ADVATEDrug

    50 international units (IU)/kg, a single dose.

  • FRSW107Drug

    50 IU/kg, a single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum measured concentration of FVIII:C (Cmax)Time frame: Pre-dose and post dose up to 8 days.
  2. Time required for the concentration of the drug to reach half of its original value (T1/2)Time frame: Pre-dose and post dose up to 8 days
  3. Area Under the Curve to Infinity (AUC)Time frame: Pre-dose and post dose up to 8 days.
  4. The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL).Time frame: Pre-dose and post dose up to 8 days.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Shenzhen Children's Hospita

    Shenzhen, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangzhou, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.